Welcome, visitor! [ Login

Dragon Acquires Remaining 25 % of Nanjing Huaxin Biopharmaceutical Co., Ltd.

News

Dragon Pharmaceuticals Inc. (OTCBB :DRUG.OB) announces that it has acquired the remaining 25% of equity interest in Nanjing Huaxin Bio-pharmaceutical Co., Ltd. (“Huaxin”), an integrated biotech company with a GMP-certified production facility located in Nanjing, China. Combined with the 75% interest acquired in 1999, Dragon now owns 100% of Huaxin. The acquisition reaffirms Dragon’s current commitment to Huaxin and will allow Dragon to meet the growing demand for its commercially available therapeutic protein, Epoetin-Alfa (EPO), and expedite the development of other pipeline products. Dragon acquired the remaining 25% interest in Huaxin for US $1.4 million.

Dragon also reports the progress of other products under development including thrombopoietin (TPO), granulocyte-colony stimulating factor (G-CSF), human insulin, slow-release EPO and Hepatitis B vaccine.

TPO is a protein that is produced mainly by the liver to stimulate the production of platelets by bone marrow. Dragon is optimizing its TPO cell lines and intends to complete all pre-clinical testing in 2002.

G-CSF stimulates the bone marrow to produce white blood cells that help fight infection and disease. Dragon recently completed the G-CSF cell line development. Worldwide annual sales for G-CSF are over US $1 billion.

Insulin is a peptide hormone secreted by the pancreas that allows the body to regulate blood sugar levels. Dragon has developed a Pichia yeast cell line for insulin and is set to begin animal studies and other pre-clinical testing. Annual global sales of recombinant human insulin are over US $3 billion.

Both conventional and slow-release EPO stimulate red blood cell production in patients with anemia related to kidney failure, chemotherapy and surgery. Slow-release EPO has the added advantage of requiring significantly fewer doses than conventional EPO. Dragon is currently working with Renapharm AB of Sweden and Transworld Pharmaceuticals of Portugal to finalize the formulation for the slow-release product and expects to enter human clinical trials in 2003.

Dragon’s acquisition of the remaining 25% in Huaxin reflects the Board of Directors’ current commitment to produce and market EPO as well as to develop the products discussed above. As a result of this commitment, the Board of Directors has decided not to pursue the Hepatitis B vaccine project with Alphatech Bioengineering Limited. Because Dragon has decided not to pursue this project, it will be repaid the US $4 million purchase price with interest.

Buy Dragon Pharma Steroids

Online Dragon Pharma Anabolic Steroid – pharmaceutical company that manufactures steroid gear: Shop Deca 300 Online.

No Tags

12 total views, 1 today

  

  • Dragon Pharma Sells Polymun Development

    Dragon Pharmaceutical Inc. (OTC BB: DRUG; TSX: DDD) (“the Company”) announced today that the Company has sold its Development and Manufacturing Agreement with Polymun Scientific Immunbiologische Forschung GmBh (“Polymun”) to AS Biotech AG, a Swiss company, for US$1 million. Prior to the acquisition of Oriental Wave Holding Limited in early 2005, Dragon entered into a […]

  • Dragon Announces Growth in International EPO Sales

    Dragon Pharmaceuticals Inc. (NASDAQ OTC: DRUG) today announced the receipt of EPO sales orders from international markets outside of China totaling $937,500 in the first quarter of 2002, representing a 113% increase over total year international sales of $440,125 in 2001. To date, the Company has completed EPO shipments for $847,500 of first quarter orders, […]

  • Dragon Ships EPO Internationally

    Dragon Pharmaceuticals Inc. (NASDAQ OTC: DRUG) today announced that it has filled orders for recombinant erythropoietin (EPO) from Egypt, India and Peru where, in addition to China, the Company’s EPO is approved for use in the treatment of anemia related to chronic renal failure. All dollar amounts are stated in US dollars. “Penetrating new markets […]

  • Dragon Pharmaceutical Inc. Announces 2002 Fourth Quarter and Full Year Results

    Dragon Pharmaceutical Inc. (TSX: DDD; OTC BB: DRUG) today announced results for the three-month and twelve-month periods ending December 31, 2002. 2002 Highlights Generated revenues of $7.36 million, representing significant growth from $3.07 million in 2001. Enhancement of gross margin in 2002 to 86.7% from 81% in 2001. Reported a first ever operating profit of […]

  • Dragon Announces Participation at Biopartnering Europe 2001

    Dragon Pharmaceuticals Inc. (OTC BB – DRUG.OB) is pleased to announce that it has been invited to present at the BioPartnering Europe 2001 conference to be held at the Queen Elizabeth II Conference Centre in London, England from October 14th to 16th, 2001. BioPartnering Europe is the premier European venue for showcasing innovative biopharmaceutical and […]

Dragon Pharma Suppliers

dragon pharma source
american steroids online
real dragon pharma supplier
dragon pharma for sale
dragon pharma legit supplier
buy dragon pharma
dragon pharma store
buy steroids
dragon pharma legit dragon pharma anabolics